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Abstract
Medullary thyroid cancer (MTC) accounts for 5–10% of all thyroid cancers. The majority of medullary
thyroid cancers are sporadic, but 25% of cases are inherited as a result of germline mutations in the
RET proto-oncogene. In sporadic cases MTC presents as a thyroid nodule discovered at palpation or
at thyroid ultrasonography, and is indistinguishable from thyroid nodules of different histology. Since
effective treatment of MTC is only possible when the tumour is limited to the thyroid gland, early
discovery has a decisive impact on how radical initial surgical treatment needs to be. Recent data
suggest that in sporadic cases, early discovery of thyroid nodular disease is possible when screening
serum calcitonin measurement, while screening for germline RET proto-oncogene mutations is
fundamental in first degree relatives of patients with hereditary MTC.
Introduction and context
Medullary thyroid cancer (MTC) is a malignant tumour
originating from the calcitonin producing parafollicular
(C) cells of the thyroid. Among well-differentiated
thyroid carcinomas, it is the most aggressive, with
survival rates of 40–50% at 10 years. Early diagnosis
and radical surgical treatment are key to improving
morbidity and mortality amongst patients with MTCs
[1]. Fine needle aspiration cytology (FNAC) is a very
sensitive and specific procedure for the diagnosis of
malignant thyroid nodules, but cytological typing of
MTC may be difficult with routine staining. Serum
calcitonin (CT) measurement in patients with thyroid
nodules is the most specific and sensitive marker of MTC,
having even better accuracy than FNAC in diagnosing
unsuspected MTC [2–3]. An elevated level of serum CT,
confirmed by an exaggerated response to pentagastrin
stimulation, is almost invariantly associated with MTC.
Hereditary MTC accounts for 25% of cases and is
transmitted with an autosomal dominant pattern caused
by germline mutation of the RET proto-oncongene,
coding for a transmembrane tyrosine kinase (TK)
receptor mapped to chromosome 10q11.2 [4–6]. The
hereditary form of MTC may be associated with other
endocrine neoplasias such as pheochromocytoma and
parathyroid adenomas (multiple endocrine neoplasia
type 2A, or MEN 2A), or pheochromocytoma and
mucosal neurinomas (multiple endocrine neoplasia
type 2B, or MEN 2B). Alternatively, the hereditary form
may be the only manifestation of the disease (familial
MTC, or FMTC) [7].
In 1987, the MEN2A gene was assigned by linkage
analysis to the pericentromeric region of chromosome
10 [8,9]. In 1993, MEN 2A and FMTC were shown to be
associated with mutations in exon 10 or 11 of the RET
proto-oncogene, and specific RET mutations were
detected in affected families [4,5]. Subsequently, RET
proto-oncogene mutation was also found to be involved
in MEN 2B [6].
The proto-oncogene RET comprises 21 exons and
encodes a receptor TK that has a large extracellular
domain, a single transmembrane region, and two
cytoplasmic TK domains. Approximately 95% of
MEN2A families have mutations involving exons 10
(codons 609, 611, 618, and 620) and 11 (codon 634) of
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domain of the RET receptor. RET mutations that affect
the intracellular TKdomain, however, are rare. Mutations
that involve the cysteine-rich extracellular domain of the
RET receptor are thought to cause disease through
constitutive dimerization and activation of the receptor.
The FMTC phenotype is associated with mutations
involving both the extracellular cysteine-rich and intra-
cellular TK domains of the RET receptor. These muta-
tions are located in exons 10 (codons 618 and 620), 11
(codons 630, 631, and 634), 13 (codons 768, 790, and
791), 14 (codons 804 and 844), and 15 (codon 891).
95% of cases of MEN 2B are associated with a point
mutation in the methionine residue in exon 16 (codon
918) in the intracellular TK domain of RET; this is
thought to induce tumour formation by altering the
substrate specificity of the kinase domain, thereby
activating growth-stimulating pathways [10].
Recent advances
Recently, the European Thyroid Association (ETA) has
included routine measurement of serum CT in the
diagnostic evaluation of thyroid nodules. In contrast
with ETA [11] recommendations, the American Thyroid
Association (ATA) guidelines are neither in favor nor
against routine measurement of serum CT in patients
with thyroid nodules [12], although a recent American
study [13] demonstrated that it has a cost effectiveness
comparable to thyroid stimulating hormone (TSH)
measurement, mammography and colonoscopy screen-
ing. This study is the first effort to measure the cost
effectiveness of CT screening in the USA. Evidence such
as this is essential and should prompt physicians to
screen thyroid nodules by serum CT measurement in
their clinic, and should contribute to the improvement
of practice guidelines.
Another recent study suggests extending the screening for
the RET proto-oncogene to every patient with MTC. Since
1993, screening for the germline RET mutation has been
introduced to define the hereditary nature of an MTC
tumour in the first affected family member that seeks
medical attention (the proband) and, where positive,
to search for additional family members carrying
the mutation (50% risk of carrying the mutation). If
the screening is performed early in life, it can identify the
member at risk even before development of the disease,
or at least at an earlier stage. The practical consequence is
the possibility of performing prophylactic total thyroid-
ectomy or beginning early treatment of the limited
disease. RET genetic screening is also indicated in
patients apparently presenting with the sporadic form.
Elisei et al. [14] demonstrated that germline RET
mutations are present in 7.3% of patients erroneously
diagnosed with sporadic MTC. Reclassifying this form as
hereditary has a great clinical impact on the discovery of
new MTC families.
Although the entire spectrum of genetic alterations
causing sporadic MTC has not yet been defined, nearly
50% of sporadic MTCs harbour a somatic point
mutation of the RET proto-oncogene. It is reported that
patients with sporadic MTCs carrying a somatic RET
mutation have a worse outcome compared with patients
who have RET negative tumours [15–17]. The identifica-
tion of the RET mutation in the DNA extracted from
FNAC could help in planning a more aggressive surgical
strategy in RET-positive cases, hopefully improving the
long-term survival.
Implications for clinical practice
In conclusion, early diagnosis is mandatory for effective
treatment of MTC. In sporadic cases this can be achieved
through routine screening of thyroid nodules by serum
CT and in familial cases by genetic RET screening of
family members of a proband with hereditary MTC. In
addition, the screening of tumour DNA from all MTC
patients for RET somatic mutations may not only help to
distinguish sporadic MTCs from familial forms (with
important clinical and predictive consequences), but will
also be useful in the prediction of clinical outcomes and
designing therapy for patients with certain sporadic
tumours carrying a RET somatic mutation [15].
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